Common origin but individual outcomes: time for new guidelines in personalized healthcare

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Costigliola V, Gahan P, Golubnitschaja O: Predictive Medicine as the New Philosophy in Healthcare. In: Predictive Diagnostics and Personalized Treatment: Dream or Reality? Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009).▪ Overall concept of predictive, preventive and personalized medicine as the medicine of future: the key stakeholders and coordinated measures are presented.
  Google Scholar
• 2  Golubnitschaja O: Time for new guidelines in advanced diabetes care: paradigm change from delayed interventional approach to predictive, preventive and personalized medicine. EPMA J.1,3–12 (2010).▪ Overview of the most advanced technologies in predictive diagnostics, targeted preventive measures and individualized treatment algorithms in desirable diabetes care.
  MedlineGoogle Scholar
• 3  Charmandari E, Tsigos C, Chrousos G: Endocrinology of the stress response. Annu. Rev. Physiol.67,259–284 (2005).
  Medline CASGoogle Scholar
• 4  Kultz D: Molecular and evolutionary basis of the cellular stress response. Annu. Rev. Physiol.67,225–257 (2005).
  MedlineGoogle Scholar
• 5  Kultz D: Evolution of the cellular stress proteome: from monophyletic origin to ubiquitous function. J. Exp. Biol.206,3119–3124 (2003).
  MedlineGoogle Scholar
• 6  Golubnitschaja O: Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. Amino Acids32,359–371 (2007).
  Medline CASGoogle Scholar
• 7  Massague J: G1 cell-cycle control and cancer. Nature432,298–306 (2004).
  Medline CASGoogle Scholar
• 8  Golubnitschaja O, Flammer J: What are the biomarkers in glaucoma? Surv. Ophthalmol.52(Suppl. 2),155–161 (2007).
  Google Scholar
• 9  Golubnitschaja O, Yeghiazaryan K, Orgül S et al.: What are the biomarkers for glaucoma? In: Predictive Diagnostics and Personalized Treatment: Dream or Reality. Golubnitshaja O (Ed.). Nova Science Publishers, NY, USA (2009).
  Google Scholar
• 10  Peeva V, Golubnitschaja O: Birth asphyxia as the most frequent perinatal complication. In: Predictive Diagnostics and Personalized Treatment: Dream or Reality. Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009).
  Google Scholar
• 11  Thompson DG: Consequences of perinatal asphyxia. AACN Clin. Issues Crit. Care Nurs.5,242–245 (1994).
  Medline CASGoogle Scholar
• 12  Simon NP: Long-term neurodevelopmental outcome of asphyxiated newborns. Clin. Perinatol.26,767–778 (1999).
  Medline CASGoogle Scholar
• 13  Maneru C, Junque C, Botet F et al.: Neuropsychological long-term sequelae of perinatal asphyxia. Brain. Inj.15,1029–1039 (2001).
  Medline CASGoogle Scholar
• 14  Nouri S, Mahdhaoui N, Beizig S et al.: Acute renal failure in full term neonates with perinatal asphyxia. Prospective study of 87 cases. Arch. Pediatr.15,229–235 (2008).
  Medline CASGoogle Scholar
• 15  Børke WB, Munkeby BH, Mørkrid L et al.: Resuscitation with 100% O₂ does not protect the myocardium in hypoxic newborn piglets. Arch. Dis. Child. Fetal Neonatal Ed.89,156–160 (2004).
  Google Scholar
• 16  Lubec B, Chiappe-Gutierrez M, Hoeger H et al.: Glucose transporters, hexokinases and phosphofructokinase in brain or rats with perinatal asphyxia. Pediatr. Res.47,84–88 (2000).
  Medline CASGoogle Scholar
• 17  Seidl R, Stockler-Ipsiroglu S, Rolinski B et al.: Energy metabolism in graded perinatal asphyxia of the rat. Life Sci.67,421–435 (2000).
  Medline CASGoogle Scholar
• 18  Numagami Y, Zubrow AB, Mishra OP et al.: Lipid free radical generation and brain cell membrane alteration following nitric oxide synthase inhibition during cerebral hypoxia in the newborn piglet. J. Neurochem.69,1542–1547 (1997).
  Medline CASGoogle Scholar
• 19  Akhter W, Ashraf QM, Zanelli SA et al.: Effect of graded hypoxia on cerebral cortical genomic DNA fragmentation in newborn piglets. Biol. Neonate79,187–193 (2001).
  Medline CASGoogle Scholar
• 20  Labudova O, Schuller E, Yeghiazaryan K et al.: Genes involved in the pathophysiology of perinatal asphyxia. Life Sci.64,1831–1838 (1999).
  Medline CASGoogle Scholar
• 21  Lubec B, Labudova O, Hoeger H et al.: Expression of transcription factors in the brain of rats with perinatal asphyxia. Biol. Neonate81,266–278 (2002).
  Medline CASGoogle Scholar
• 22  Andersson K, Blum M, Chen Y et al.: Perinatal asphyxia increases bFGF mRNA levels and DA cell body number in the mesencephalon of rats. Neuroreport6,375–378 (1995).
  Medline CASGoogle Scholar
• 23  Cheng Y, Gidday JM, Yan Q et al.: Marked age-dependent neuroprotection by brain-derived neurotrophic factor against neonatal hypoxic-ischemic brain injury. Ann. Neurol.41,521–529 (1997).
  Medline CASGoogle Scholar
• 24  Gluckman PD, Guan J, Williams C et al.: Asphyxial brain injury – the role of the IGF system. Mol. Cell. Endocrinol.140,95–99 (1998).
  Medline CASGoogle Scholar
• 25  Gustafson K, Hagberg H, Bengtsson BA et al.: Possible protective role of growth hormone in hypoxia-ischemia in neonatal rats. Pediatr. Res.45,318–323 (1999).
  Medline CASGoogle Scholar
• 26  Morales P, Klawitter V, Johansson S et al.: Perinatal asphyxia impairs connectivity and dopamine neurite branching in organotypic triple culture from rat substantia nigra. Neurosci. Lett.348,175–179 (2003).
  Medline CASGoogle Scholar
• 27  Morales P, Reyes P, Klawitter V et al.: Effects of perinatal asphyxia on cell proliferation and neuronal phenotype evaluated with organotypic hippocampal cultures. Neuroscience135,421–431 (2005).
  Medline CASGoogle Scholar
• 28  Klawitter V, Morales P, Johansson S et al.: Effect of perinatal asphyxia on cell survival, neuronal phenotype and neurite growth evaluated with organotypic triple cultures. Amino Acids28,149–155 (2005).
  Medline CASGoogle Scholar
• 29  Yeghiazaryan K, Peeva V, Morelli M et al.: Potential targets for early diagnosis and neuroprotection in asphyxiated newborns. In: Predictive Diagnostics and Personalized Treatment: Dream or Reality. Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009).
  Google Scholar
• 30  Lee AC, Mullany LC, Tielsch JM et al.: Risk factors for neonatal mortality due to birth asphyxia in southern Nepal: a prospective, community-based cohort study. Pediatrics121,1381–1390 (2008).
  Google Scholar
• 31  Beltrame JF, Sasayama S, Maseri A: Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J. Am. Coll. Cardiol.33,1442–1452 (1999).
  Medline CASGoogle Scholar
• 32  Flammer J: Glaucoma. A guide for patients. An Introduction For Care Providers. A Quick Reference (3rd Edition). Bern, Hogrefe and Huber Publishers, Göttingen, Germany (2006).
  Google Scholar
• 33  Flammer J, Pache M, Resink T: Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog. Retin. Eye Res.20,319–349 (2001).
  Medline CASGoogle Scholar
• 34  Teuchner B, Orgül S, Ulmer H et al.: Reduced thirst in patients with a vasospastic syndrome. Acta Ophthalmol. Scand.82,738–740 (2004).
  MedlineGoogle Scholar
• 35  Wunderlich K, Zimmerman C, Gutmann H et al.: Vasospastic persons exhibit differential expression of ABC-transport proteins. Mol. Vis.9,756–761 (2003).
  Medline CASGoogle Scholar
• 36  Flammer J: Innovative glaucoma therapy. Ophthalmologe98,923–924 (2001).
  Medline CASGoogle Scholar
• 37  Yeghiazaryan K, Flammer J, Golubnitschaja O: Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalized medicine to effective costs. EPMA J.1(2),263–272 (2010).
  MedlineGoogle Scholar
• 38  Golubnitschaja O, Yeghiazaryan K, Wunderlich K et al.: Disease proteomics reveals altered basic gene expression regulation in leukocytes of glaucoma patients. Proteomics Clin. Appl.1,1316–1323 (2007).
  Medline CASGoogle Scholar
• 39  Gahan PB: Circulating nucleic acids in plasma and serum: roles in diagnosis and prognosis. In: Diagnostics and Personalized Treatment: Dream or Reality. Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009).▪ Overview of circulating nucleic acids in plasma and serum-related strategies as one of the most potent approaches to diagnose severe pathologies and to prognose the efficacy of personalized treatments.
  Google Scholar
• 40  Golubnitschaja O: Diabetes mellitus, introduction. In: Predictive Diagnostics and Personalized Treatment: Dream or Reality? Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009).
  Google Scholar
• 41  Golubnitschaja O: Advanced diabetes care: three levels of prediction, prevention and personalized treatment. Curr. Diabetes Rev.6,42–51 (2010).
  MedlineGoogle Scholar
• 42  George B, Cebioglu M, Yeghiazaryan K: Inadequate diabetic care: global figures cry for preventive measures and personalized treatment. EPMA J.1,13–18 (2010).
  MedlineGoogle Scholar
• 43  Cebioglu M, Schild HH, Golubnitschaja O: Diabetes mellitus as a risk factor for cancer: is predictive diagnosis possible? In: Predictive Diagnostics and Personalized Treatment: Dream or Reality? Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009).
  Google Scholar
• 44  van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR: Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int. J. Cancer120,1986–1992 (2007).
  Medline CASGoogle Scholar
• 45  Cebioglu M, Schild HH, Golubnitschaja O: Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J.1,130–137 (2010).▪ Innovative view over cancer origin: risk factors and molecular pathomechanisms are discussed.
  MedlineGoogle Scholar
• 101  European Association for Predictive, Preventive & Personalized Medicine www.epmanet.eu
  Google Scholar